Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Multicolored pills Iryna Imago/Shutterstock.com

Late last year, the Third Circuit Court of Appeals, in In re Avandia Mktg., Sales & Prods. Liab. Litig., became one of the first circuit courts in the country to tackle the thorny issue of preemption following the U.S. Supreme Court’s “clarifying” language in Merck. In doing so, the court reversed a district court’s ruling in favor of preemption and revived 10-year old claims made by two health-care plans against GlaxoSmithKline (GSK) over its marketing of the diabetes drug Avandia. The decision is important for its interpretation of the high court’s recent guidance for what constitutes “clear evidence” in cases of alleged preemption and for its persuasive authority in other jurisdictions.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 3 articles* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?

Law Firms Mentioned


Online New Jersey Legal Reference LibraryBook

Start your One Month Free Trial Today. Call 877-807-8076 or email ljpsales@lawjournalpress.comOur best-selling high-quality legal content is now available in the fo...

Get More Information

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.